2012 Q4 Form 10-Q Financial Statement
#000110465912073746 Filed on November 02, 2012
Income Statement
Concept | 2012 Q4 | 2012 Q3 | 2011 Q4 |
---|---|---|---|
Revenue | $1.090M | $91.00K | $42.00K |
YoY Change | 2495.24% | 727.27% | -99.13% |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $8.700M | $4.075M | $2.800M |
YoY Change | 210.71% | 171.49% | 64.71% |
% of Gross Profit | |||
Research & Development | $5.200M | $8.306M | $7.500M |
YoY Change | -30.67% | -1.41% | -17.58% |
% of Gross Profit | |||
Depreciation & Amortization | $200.0K | $154.0K | $200.0K |
YoY Change | 0.0% | -7.78% | -33.33% |
% of Gross Profit | |||
Operating Expenses | $13.80M | $12.38M | $10.30M |
YoY Change | 33.98% | 24.73% | -4.63% |
Operating Profit | -$12.29M | ||
YoY Change | 23.95% | ||
Interest Expense | -$800.0K | $880.0K | -$500.0K |
YoY Change | 60.0% | 76.35% | -83.87% |
% of Operating Profit | |||
Other Income/Expense, Net | $0.00 | -$1.192M | $100.0K |
YoY Change | -100.0% | 405.08% | -80.0% |
Pretax Income | -$13.50M | -$13.50M | -$10.70M |
YoY Change | 26.17% | 32.35% | 24.42% |
Income Tax | $0.00 | $0.00 | -$16.20M |
% Of Pretax Income | |||
Net Earnings | -$13.51M | -$13.48M | $81.98M |
YoY Change | -116.48% | 38.5% | -1053.2% |
Net Earnings / Revenue | -1239.63% | -14815.38% | 195178.57% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$507.5K | -$316.2K | $3.431M |
COMMON SHARES | |||
Basic Shares Outstanding | 24.53M shares | 24.46M shares | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2012 Q4 | 2012 Q3 | 2011 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $88.50M | $60.70M | $48.50M |
YoY Change | 82.47% | 267.88% | 48.32% |
Cash & Equivalents | $40.30M | $23.41M | $48.54M |
Short-Term Investments | $48.20M | $37.30M | $0.00 |
Other Short-Term Assets | $1.100M | $1.700M | $900.0K |
YoY Change | 22.22% | -62.22% | -87.14% |
Inventory | $1.152M | $26.00K | |
Prepaid Expenses | |||
Receivables | $11.00K | $500.0K | $128.0K |
Other Receivables | $700.0K | $0.00 | $0.00 |
Total Short-Term Assets | $91.46M | $62.89M | $49.40M |
YoY Change | 85.15% | 152.57% | 24.12% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.421M | $1.384M | $1.310M |
YoY Change | 8.47% | 6.46% | 9.17% |
Goodwill | |||
YoY Change | |||
Intangibles | $683.0K | $740.0K | $912.0K |
YoY Change | -25.11% | ||
Long-Term Investments | $0.00 | ||
YoY Change | |||
Other Assets | $334.0K | $55.00K | $55.00K |
YoY Change | 507.27% | -98.92% | -98.85% |
Total Long-Term Assets | $2.527M | $4.125M | $4.331M |
YoY Change | -41.65% | -44.26% | -39.85% |
TOTAL ASSETS | |||
Total Short-Term Assets | $91.46M | $62.89M | $49.40M |
Total Long-Term Assets | $2.527M | $4.125M | $4.331M |
Total Assets | $93.99M | $67.01M | $53.73M |
YoY Change | 74.93% | 107.47% | 14.32% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $8.000M | $10.50M | $10.10M |
YoY Change | -20.79% | 15.38% | -10.62% |
Accrued Expenses | $7.860M | $2.000M | $9.275M |
YoY Change | -15.26% | -45.95% | 562.5% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $11.80M | $11.50M | $6.800M |
YoY Change | 73.53% | 228.57% | |
Total Short-Term Liabilities | $22.98M | $24.59M | $18.77M |
YoY Change | 22.45% | 49.03% | 23.49% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $11.10M | $14.10M | $22.70M |
YoY Change | -51.1% | -83.6% | |
Other Long-Term Liabilities | $1.788M | $1.558M | $1.399M |
YoY Change | 27.81% | -32.26% | -98.16% |
Total Long-Term Liabilities | $1.788M | $1.558M | $1.399M |
YoY Change | 27.81% | -98.24% | -98.16% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $22.98M | $24.59M | $18.77M |
Total Long-Term Liabilities | $1.788M | $1.558M | $1.399M |
Total Liabilities | $36.42M | $42.38M | $44.29M |
YoY Change | -17.77% | -59.56% | -51.49% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$86.26M | -$72.74M | -$39.97M |
YoY Change | 115.79% | ||
Common Stock | $31.00K | $24.00K | $2.000K |
YoY Change | 1450.0% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $57.57M | $24.63M | $9.443M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $93.99M | $67.01M | $53.73M |
YoY Change | 74.93% | 107.47% | 14.32% |
Cashflow Statement
Concept | 2012 Q4 | 2012 Q3 | 2011 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$13.51M | -$13.48M | $81.98M |
YoY Change | -116.48% | 38.5% | -1053.2% |
Depreciation, Depletion And Amortization | $200.0K | $154.0K | $200.0K |
YoY Change | 0.0% | -7.78% | -33.33% |
Cash From Operating Activities | -$16.10M | -$11.30M | -$8.300M |
YoY Change | 93.98% | 24.18% | -29.06% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$200.0K | -$400.0K | -$200.0K |
YoY Change | 0.0% | 300.0% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$9.100M | -$9.900M | $25.60M |
YoY Change | -135.55% | -194.29% | 122.61% |
Cash From Investing Activities | -$9.400M | -$10.30M | $25.40M |
YoY Change | -137.01% | -199.04% | 120.87% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 42.40M | -2.300M | 14.90M |
YoY Change | 184.56% | 76.92% | -1246.15% |
NET CHANGE | |||
Cash From Operating Activities | -16.10M | -11.30M | -8.300M |
Cash From Investing Activities | -9.400M | -10.30M | 25.40M |
Cash From Financing Activities | 42.40M | -2.300M | 14.90M |
Net Change In Cash | 16.90M | -23.90M | 32.00M |
YoY Change | -47.19% | -1283121479679999000.0% | -2233.33% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$16.10M | -$11.30M | -$8.300M |
Capital Expenditures | -$200.0K | -$400.0K | -$200.0K |
Free Cash Flow | -$15.90M | -$10.90M | -$8.100M |
YoY Change | 96.3% | 21.11% | -30.77% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
us-gaap |
Interest Expense
InterestExpense
|
1357000 | USD | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
30000 | USD | |
dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS INC | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-09-30 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
CY2012Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
24530358 | shares |
CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
48544000 | USD |
CY2011Q4 | us-gaap |
Defined Benefit Plan Current Assets
DefinedBenefitPlanCurrentAssets
|
245000 | USD |
CY2011Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
338000 | USD |
CY2011Q4 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
144000 | USD |
CY2011Q4 | us-gaap |
Assets Current
AssetsCurrent
|
49399000 | USD |
CY2011Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1310000 | USD |
CY2011Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
912000 | USD |
CY2011Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
55000 | USD |
CY2011Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
2054000 | USD |
CY2011Q4 | us-gaap |
Assets
Assets
|
53730000 | USD |
CY2011Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10078000 | USD |
CY2011Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1547000 | USD |
CY2011Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
232000 | USD |
CY2011Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
138000 | USD |
CY2011Q4 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
6775000 | USD |
CY2011Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
18770000 | USD |
CY2011Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
465000 | USD |
CY2011Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1399000 | USD |
CY2011Q4 | us-gaap |
Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
|
245000 | USD |
CY2011Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
22711000 | USD |
CY2011Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
697000 | USD |
CY2011Q4 | us-gaap |
Liabilities
Liabilities
|
44287000 | USD |
CY2011Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
49000 | USD |
CY2011Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | USD |
CY2011Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
49362000 | USD |
CY2011Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
1000 | USD |
CY2011Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-39971000 | USD |
CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9443000 | USD |
CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
53730000 | USD |
CY2012Q3 | us-gaap |
Assets Current
AssetsCurrent
|
62889000 | USD |
CY2012Q3 | us-gaap |
Assets
Assets
|
67014000 | USD |
CY2011Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10592000 | USD |
CY2012Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
24590000 | USD |
CY2012Q3 | us-gaap |
Liabilities
Liabilities
|
42383000 | USD |
CY2012Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24631000 | USD |
CY2012Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
67014000 | USD |
CY2011Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2011Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
49625000 | shares |
CY2011Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
49000000 | shares |
CY2011Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
49000000 | shares |
CY2011Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2011Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
62625000 | shares |
CY2011Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1662321 | shares |
CY2011Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1662321 | shares |
CY2012Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
65000000 | shares |
CY2012Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2012Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2012Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2012Q3 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
0 | USD |
CY2012Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2012Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2012Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
24466049 | shares |
CY2012Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
24466049 | shares |
CY2011Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
11000 | USD |
CY2012Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
91000 | USD |
us-gaap |
Sales Revenue Net
SalesRevenueNet
|
391000 | USD | |
CY2011Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8425000 | USD |
CY2011Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
1501000 | USD |
CY2011Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
9926000 | USD |
CY2011Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9915000 | USD |
CY2011Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3000 | USD |
CY2011Q3 | us-gaap |
Interest Expense
InterestExpense
|
499000 | USD |
CY2011Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
260000 | USD |
CY2011Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-236000 | USD |
CY2011Q3 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-10151000 | USD |
CY2011Q3 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
417000 | USD |
CY2011Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9734000 | USD |
CY2011Q3 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
858000 | USD |
CY2012Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
12381000 | USD |
CY2012Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12290000 | USD |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
29817000 | USD | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-29426000 | USD | |
CY2012Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1192000 | USD |
CY2012Q3 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-13482000 | USD |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3345000 | USD | |
us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-32771000 | USD | |
CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13482000 | USD |
CY2012Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13482000 | USD |
us-gaap |
Sales Revenue Net
SalesRevenueNet
|
761000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-32771000 | USD | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-33914000 | USD | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
23126000 | USD | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
5143000 | USD | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
28269000 | USD | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-27508000 | USD | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
29000 | USD | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1298000 | USD | |
us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-28806000 | USD | |
us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
646000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-28160000 | USD | |
us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
2573000 | USD | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-30733000 | USD | |
CY2012Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.55 | |
CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.55 | |
us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-2.36 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.36 | ||
CY2011Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1595821 | shares |
CY2012Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24464281 | shares |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1594288 | shares | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
14356546 | shares | |
CY2012Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-35000 | USD |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-29000 | USD | |
CY2012Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-13517000 | USD |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-32800000 | USD | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-28158000 | USD | |
CY2011Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9735000 | USD |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"> </p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1. Organization and Business</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Supernus Pharmaceuticals, Inc. (the Company) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company has two proprietary products and several proprietary product candidates in clinical development that address large market opportunities in epilepsy and attention deficit hyperactivity disorder. Trokendi XR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1">TM</font><font style="FONT-SIZE: 10pt" size="2"> (formerly known as SPN-538) received tentative approval from the Food and Drug Administration (the FDA) on June 25, 2012, and Oxtellar XR</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1">TM</font><font style="FONT-SIZE: 10pt" size="2"> was approved by the FDA on October 19, 2012 (See footnote 8).</font></p></td></tr></table> | ||
us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
2888000 | USD | |
us-gaap |
Interest Paid
InterestPaid
|
2257000 | USD | |
us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
49000 | USD | |
us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-766000 | USD | |
CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23740000 | USD |
CY2011Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16484000 | USD |
us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
29000 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
650000 | USD | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
248000 | USD | |
CY2012Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23412000 | USD |
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-31059000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-31059000 | USD | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
52447000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-39613000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
45540000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
516000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
45540000 | USD | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-25132000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
235000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
938000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
660000 | USD | |
us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
101000 | USD | |
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
259000 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
158000 | USD | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
56476000 | USD | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
17416000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
553000 | USD | |
CY2012Q3 | us-gaap |
Long Term Investments
LongTermInvestments
|
1804000 | USD |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The preparation of the financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair value of assets and common stock, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions, including information received from its service providers, which it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p></td></tr></table> | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Concentration of Credit Risk</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. The counterparties are various corporations and financial institutions of high credit standing.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Substantially all of the Company’s cash and cash equivalents are maintained with well known, U.S. and Non U.S. financial institutions and corporations. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, management believes they bear minimal risk. The Company has not experienced any other than temporary losses on its deposits of cash, cash equivalents, short-term investments and restricted investments.</font></p></td></tr></table> | ||
us-gaap |
Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
|
P10Y | ||
CY2012Q3 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | USD |
us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
150000 | USD | |
CY2011Q3 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | USD |
us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
750000 | USD | |
CY2011Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
5746000 | USD |
CY2012Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6298000 | USD |
CY2011Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4436000 | USD |
CY2012Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4914000 | USD |
CY2012Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1384000 | USD |
CY2012Q3 | us-gaap |
Depreciation
Depreciation
|
154000 | USD |
us-gaap |
Depreciation
Depreciation
|
478000 | USD | |
CY2011Q3 | us-gaap |
Depreciation
Depreciation
|
167000 | USD |
us-gaap |
Depreciation
Depreciation
|
479000 | USD | |
CY2011Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2292000 | USD |
CY2011Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1380000 | USD |
CY2012Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2292000 | USD |
CY2012Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1552000 | USD |
CY2012Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
57000 | USD |
CY2011Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
57000 | USD |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
172000 | USD | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
172000 | USD | |
CY2012Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
740000 | USD |
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
25000 | USD | |
us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
10000 | USD | |
us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
-1000 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
651000 | USD | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
159000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
-44000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
137000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2471000 | USD | |
us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
138000 | USD | |
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
439000 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
553000 | USD | |
us-gaap |
Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
|
2141000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27927000 | USD | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
17890000 | USD | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
26855000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
494000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
8471000 | USD | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1000 | USD | |
CY2012Q3 | us-gaap |
Inventory Net
InventoryNet
|
26000 | USD |
us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
705000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
14296000 | USD | |
us-gaap |
Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
|
-2096000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
12200000 | USD | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-7256000 | USD | |
us-gaap |
Interest Paid
InterestPaid
|
990000 | USD | |
us-gaap |
Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
|
9044000 | USD | |
CY2012Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
238000 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
91000 | USD | |
CY2012Q3 | us-gaap |
Interest Expense
InterestExpense
|
880000 | USD |
CY2012Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
55000 | USD |
CY2012Q3 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
142000 | USD |
CY2012Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10485000 | USD |
CY2012Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1801000 | USD |
CY2012Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
576000 | USD |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
11450000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-30068000 | USD | |
CY2012Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
39000 | USD |
CY2012Q3 | us-gaap |
Defined Benefit Plan Current Assets
DefinedBenefitPlanCurrentAssets
|
275000 | USD |
CY2012Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1276000 | USD |
CY2012Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
37256000 | USD |
CY2011Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
128000 | USD |
CY2012Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
500000 | USD |
CY2012Q3 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
144000 | USD |
CY2012Q3 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
11490000 | USD |
CY2012Q3 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
381000 | USD |
CY2012Q3 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
14116000 | USD |
CY2012Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1558000 | USD |
CY2012Q3 | us-gaap |
Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
|
275000 | USD |
CY2012Q3 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
1463000 | USD |
CY2012Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
24000 | USD |
CY2012Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
97378000 | USD |
CY2012Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-29000 | USD |
CY2012Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-72742000 | USD |
CY2011Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-1000 | USD |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
2000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
372000 | USD | |
CY2012Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8306000 | USD |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18367000 | USD | |
CY2012Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
4075000 | USD |
us-gaap |
Interest Expense
InterestExpense
|
2771000 | USD | |
CY2012Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-351000 | USD |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-665000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
8471000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-39613000 | USD | |
us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
1143000 | USD | |
CY2011Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-6.90 | |
us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-19.68 | ||
CY2011Q3 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
|
0.26 | |
us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
|
0.40 | ||
CY2011Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-6.64 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-19.28 | ||
us-gaap |
Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
|
-4019000 | USD | |
us-gaap |
Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
|
15000000 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
26000 | USD | |
supn |
Number Of Proprietary Products Addressing Large Market Opportunities In Epilepsy And Attention Deficit Hyperactivity Disorder
NumberOfProprietaryProductsAddressingLargeMarketOpportunitiesInEpilepsyAndAttentionDeficitHyperactivityDisorder
|
2 | item |